Coloplast sales rise 20%, profits 61%
This article was originally published in Clinica
Executive Summary
Danish medical device manufacturer Coloplast reported sales up 20% in the six months to the end of March to DKr 936.9 million ($160 million). Excluding skincare products sales from US subsidiary Sween, which was acquired in early 1995, Coloplast's sales rose 13%. Pre-tax profit in the first six months was DKr 110 million, up 61%. The strongest sales growth was seen in woundcare, up 24%, followed by incontinence products, up 19%, and ostomy sales, up 13%. Sales of breast care products increased 8%. Coloplast has confirmed earlier forecasts of sales and profit growth of more than 15% during fiscal 1996.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.